TOCILIZUMAB ACHIEVES BETTER REPAIR OF FOCAL BONE EROSIONS THAN TUMOUR NECROSIS FACTOR INHIBITION IN RA PATIENTS - DATA FROM THE PROSPECTIVE REBONE STUDY ON EROSION REPAIR

Schett G, Finze S, Kraus S, Regensburger A, Kocijan R, Rech J (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 77

Pages Range: 572-572

DOI: 10.1136/annrheumdis-2018-eular.3188

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III Sebastian Kraus Lehrstuhl für Innere Medizin III Adrian Regensburger Lehrstuhl für Innere Medizin III Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Medizinische Universität Wien AT Austria (AT) Albert-Ludwigs-Universität Freiburg DE Germany (DE)

How to cite

APA:

Schett, G., Finze, S., Kraus, S., Regensburger, A., Kocijan, R., & Rech, J. (2018). TOCILIZUMAB ACHIEVES BETTER REPAIR OF FOCAL BONE EROSIONS THAN TUMOUR NECROSIS FACTOR INHIBITION IN RA PATIENTS - DATA FROM THE PROSPECTIVE REBONE STUDY ON EROSION REPAIR. (pp. 572-572).

MLA:

Schett, Georg, et al. "TOCILIZUMAB ACHIEVES BETTER REPAIR OF FOCAL BONE EROSIONS THAN TUMOUR NECROSIS FACTOR INHIBITION IN RA PATIENTS - DATA FROM THE PROSPECTIVE REBONE STUDY ON EROSION REPAIR." 2018. 572-572.

BibTeX: Download